313 related articles for article (PubMed ID: 26210103)
21. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ; Graf RP; Villacampa G; Raskina K; Sokol E; Jin D; Antonarakis ES; Li G; Huang RSP; Casanova-Salas I; Vivancos A; Carles J; Ross JS; Schrock AB; Oxnard GR; Mateo J
JCO Precis Oncol; 2022 Jul; 6():e2200195. PubMed ID: 35820087
[TBL] [Abstract][Full Text] [Related]
22. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
23. Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Varnai R; Sipeky C
Pharmacogenomics; 2020 Oct; 21(15):1101-1115. PubMed ID: 33021139
[TBL] [Abstract][Full Text] [Related]
24. [Molecular biology of castration-resistant prostate cancer].
Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
[TBL] [Abstract][Full Text] [Related]
25. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
26. Clinical phenotypes of castration-resistant prostate cancer.
Zhang T; Armstrong AJ
Clin Adv Hematol Oncol; 2013 Nov; 11(11):707-18. PubMed ID: 24896544
[TBL] [Abstract][Full Text] [Related]
27. Integrative clinical genomics of advanced prostate cancer.
Robinson D; Van Allen EM; Wu YM; Schultz N; Lonigro RJ; Mosquera JM; Montgomery B; Taplin ME; Pritchard CC; Attard G; Beltran H; Abida W; Bradley RK; Vinson J; Cao X; Vats P; Kunju LP; Hussain M; Feng FY; Tomlins SA; Cooney KA; Smith DC; Brennan C; Siddiqui J; Mehra R; Chen Y; Rathkopf DE; Morris MJ; Solomon SB; Durack JC; Reuter VE; Gopalan A; Gao J; Loda M; Lis RT; Bowden M; Balk SP; Gaviola G; Sougnez C; Gupta M; Yu EY; Mostaghel EA; Cheng HH; Mulcahy H; True LD; Plymate SR; Dvinge H; Ferraldeschi R; Flohr P; Miranda S; Zafeiriou Z; Tunariu N; Mateo J; Perez-Lopez R; Demichelis F; Robinson BD; Schiffman M; Nanus DM; Tagawa ST; Sigaras A; Eng KW; Elemento O; Sboner A; Heath EI; Scher HI; Pienta KJ; Kantoff P; de Bono JS; Rubin MA; Nelson PS; Garraway LA; Sawyers CL; Chinnaiyan AM
Cell; 2015 May; 161(5):1215-1228. PubMed ID: 26000489
[TBL] [Abstract][Full Text] [Related]
28. Current state of castration-resistant prostate cancer.
Petrylak DP
Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
[TBL] [Abstract][Full Text] [Related]
29. Current, new and novel therapy for castration-resistant prostate cancer.
Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
[TBL] [Abstract][Full Text] [Related]
30. PARP inhibition in castration-resistant prostate cancer.
Nappi L; Gleave ME
Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
[No Abstract] [Full Text] [Related]
31. Targeted Next-Generation Sequencing in Men with Metastatic Prostate Cancer: a Pilot Study.
Barata PC; Mendiratta P; Heald B; Klek S; Grivas P; Sohal DPS; Garcia JA
Target Oncol; 2018 Aug; 13(4):495-500. PubMed ID: 29974386
[TBL] [Abstract][Full Text] [Related]
32. [New era of the treatment of CRPC in Japan].
Akaza H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):804. PubMed ID: 25131863
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of genetic aberrations in metastatic prostate cancer.
Reichert ZR; McKay RR
Curr Opin Urol; 2019 Jul; 29(4):319-325. PubMed ID: 31158106
[TBL] [Abstract][Full Text] [Related]
35. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
Palmbos PL; Hussain MH
Oncology (Williston Park); 2016 May; 30(5):377-85. PubMed ID: 27188668
[TBL] [Abstract][Full Text] [Related]
36. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
37. [The concept and mechanisms of castration-resistant prostate cancer].
Naito S; Shiota M
Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
[TBL] [Abstract][Full Text] [Related]
38. [New therapies in metastatic castration resistant prostate cancer].
Thibault C; Massard C
Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
[TBL] [Abstract][Full Text] [Related]
39. Drug discovery in advanced prostate cancer: translating biology into therapy.
Yap TA; Smith AD; Ferraldeschi R; Al-Lazikani B; Workman P; de Bono JS
Nat Rev Drug Discov; 2016 Oct; 15(10):699-718. PubMed ID: 27444228
[TBL] [Abstract][Full Text] [Related]
40. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer.
Thelen P; Wuttke W; Seidlová-Wuttke D
J Steroid Biochem Mol Biol; 2014 Jan; 139():290-3. PubMed ID: 23872207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]